Document Detail

Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis.
MedLine Citation:
PMID:  15571587     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: Infliximab is approved for the treatment of rheumatoid arthritis (RA) and Crohn's disease (CD). We report the first large series of pregnancy outcomes in women with RA and CD exposed to infliximab. METHODS: The infliximab safety database was queried for all reports of pregnancy. Data were extracted regarding the indication for infliximab, timing of infliximab relative to conception, pregnancy course, and pregnancy outcome. The proportion of live births, miscarriages, and therapeutic terminations for women directly exposed to infliximab before or during confirmed pregnancy were compared to those expected for the general U.S. population of pregnant women and pregnant women with CD not exposed to infliximab. RESULTS: Of the 146 identified pregnancies, 131 involved women exposed directly to infliximab and outcome data were available for 96 of these women. Live births occurred in 67% (64/96), miscarriages in 15% (14/96), and therapeutic termination in 19% (18/96) of the pregnancies directly exposed to infliximab with available outcome data. These results are similar to those expected for the general U.S. population of pregnant women or pregnant women with CD not exposed to infliximab. CONCLUSION: Data from the infliximab safety database suggest that infliximab exposure during pregnancy results in outcomes that do not differ from those in the U.S. population of pregnant women and pregnant women with CD not exposed to infliximab. No increased risk of adverse outcome was detected, however, follow-up of larger numbers of pregnant women exposed to infliximab will be necessary to definitively exclude any fetal risk.
Jeffry A Katz; Christian Antoni; Gregory F Keenan; Deirdre E Smith; Stephen J Jacobs; Gary R Lichtenstein
Related Documents :
17584627 - Clinical and immunologic evaluation of women with multiple sclerosis during and after p...
382167 - Liver and gastrointestinal function in pregnancy.
21058447 - Glycogen storage disease type ia (gsd ia) during pregnancy: report of a case complicate...
12015517 - Effectiveness of inpatient and outpatient treatment strategies for women with pelvic in...
22247 - Fetal reacting bradycardia.
2708507 - Pregnancies from fallopian replacement of immature eggs with delayed intrauterine insem...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The American journal of gastroenterology     Volume:  99     ISSN:  0002-9270     ISO Abbreviation:  Am. J. Gastroenterol.     Publication Date:  2004 Dec 
Date Detail:
Created Date:  2004-12-01     Completed Date:  2005-02-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0421030     Medline TA:  Am J Gastroenterol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2385-92     Citation Subset:  IM    
Division of Gastroenterology, Case Western Reserve University, Cleveland, Ohio 44106-5066, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antirheumatic Agents / adverse effects,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*
Chi-Square Distribution
Crohn Disease / drug therapy*
Gastrointestinal Agents / adverse effects,  therapeutic use*
Pregnancy Outcome*
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antirheumatic Agents; 0/Gastrointestinal Agents; 0/infliximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and p...
Next Document:  Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: ...